<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NETILMICIN SULFATE</span><br/>(ne-til-mye'sin)<br/><span class="topboxtradename">Netromycin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">aminoglycoside antibiotic</span><br/><b>Prototype: </b>Gentamicin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Rapid-acting, broad-spectrum, semisynthetic aminoglycoside derivative. Spectrum of activity comparable to that of gentamicin,
         but netilmicin is also effective against gentamicin-resistant bacteria. Not inactivated by most strains of bacteria resistant
         to other aminoglycosides.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bactericidal action primarily against gram-negative organisms including <i>Citrobacter, Enterobacter, Escherichia coli, Klebsiella, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella, Serratia,</i> and certain gram-positive bacteria such as <i>Staphylococcus pyogenes</i> and <i>S. faecalis</i>. Like other aminoglycosides, not effective against most anaerobic bacteria (<i>Bacteroides</i> and <i>Clostridium</i> species), viruses, or fungi.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of serious or life-threatening infections including septicemia, peritonitis, intraabdominal abscess,
         lower respiratory tract infections, complicated urinary tract infection, and infections of bones, joints, and skin and its
         structures. May be administered in conjunction with a beta-lactam antibiotic (e.g., a penicillin or cephalosporin) for synergistic
         effect pending results of susceptibility testing.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity or toxic reaction to netilmicin or other aminoglycosides or to bisulfites or any other ingredient
         in the formulation; minor infections; pregnancy (category D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney function; premature infants, neonates, older adults; patients with ascites, edema, dehydration; severe burns;
         cystic fibrosis; fever; anemia; myasthenia gravis, parkinsonism; history of ear disease; infant botulism.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p> 				Note: All doses based on ideal body weight 			</p><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1.32.2 mg/kg q8h or 23.25 mg/kg q12h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> <i> 23.5 mg/kg q12h; <i>6 wk12 y,</i> 1.82.7 mg/kg q8h or 2.74 mg/kg q12h<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> &gt;70 mL/min: Reduce dose by multiplying maintenance dose by 0.85 and administer q8h; 5069 mL/min: Reduce dose by multiplying
               maintenance dose by 0.85 and administer q12 h; 2549 mL/min: Reduce dose by multiplying maintenance dose by 0.85 and
               administer q24h; <br/><span class="indicationtitle">Complicated UTI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 1.52 mg/kg q12h<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p> 			Note: Determine doses for obese patient by using ideal body weight. Use manufacturer's guidelines to adjust doses for those with
         impaired kidney function. 		
      </p><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep IM into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> <b>Adult,</b> Dilute a single dose in 50200 mL of D5W, NS, D5/NS, or RL.  							<b>Pediatric,</b> Dilute to concentration of 23 mg/mL.   
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Give over 30120 min or as ordered.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> <b>Cefepime,</b> <b> furosemide,</b> <b>heparin.</b> <span class="incompattype"> Y-site:</span> <b> Allopurinol,</b> <b>amphotericin B cholesteryl complex,</b> <b>furosemide,</b> <b>propofol.</b>
</p>
<ul>
<li>Do not use solutions that are discolored or that contain particulate matter.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Diluted solutions retain potency for up to 72 h when stored in glass containers at 15°30° C (59°86°
            F) or refrigerated.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, lethargy, drowsiness, paresthesias, tremors, muscle twitching, peripheral neuritis, disorientation, seizures, <span class="speceff-life">neuromuscular blockade</span>; musculoskeletal weakness or paralysis, respiratory <span class="speceff-life">depression or paralysis</span>. <span class="typehead">CV:</span> Palpitation, hypotension. <span class="typehead">Special Senses:</span> Ototoxicity (usually irreversible; eighth cranial nerve auditory branch: tinnitus, hearing loss, ringing, buzzing or fullness
      in ears; vestibular branch: vertigo, nystagmus, ataxia, nausea, and vomiting), blurred vision. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, stomatitis, proctitis, enterocolitis. <span class="typehead">Hematologic:</span> Increases in ALT, AST, alkaline phosphatase, bilirubin; anemia, eosinophilia, neutropenia, thrombocytopenia, thrombocytosis,
      <span class="speceff-life">agranulocytosis</span>, leukopenia, leukemoid reaction. <span class="typehead">Skin:</span> Rash, pruritus, induration, and hematoma at injection site. <span class="typehead">Urogenital:</span> <span class="speceff-life">Nephrotoxicity</span>, increase in serum creatinine and BUN; decrease in creatinine clearance; hematuria, proteinuria, urinary frequency, oliguria,
      polyuria. <span class="typehead">Body as a Whole:</span> Fever, edema, arthralgia; pain, <span class="typehead">Metabolic:</span> Hypokalemia. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Concomitant netilmicin-cephalosporin therapy may cause false elevations of <span class="alt">creatinine</span> determinations. Concomitant use of <small>BETA-LACTAMS</small> (cephalosporins, penicillins) may result in falsely low <span class="alt">aminoglycoside levels</span> (mutual inactivation may continue in body fluid specimen unless promptly assayed, or frozen, or treated with beta-lactamase).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">anesthetics</span>, <span class="classification">skeletal muscle relaxants</span> add to neuromuscular blocking effects; <b>acyclovir,</b> <b>amphotericin B,</b> <b>bacitracin,</b> <b>capreomycin,</b> <span class="classification">cephalosporins</span>, <b>colistin,</b> <b>cisplatin,</b> <b>carboplatin,</b> <b>methoxyflurane,</b> <b>polymyxin B,</b> <b>vancomycin,</b> <b>furosemide,</b> <b>ethacrynic acid</b> increase risk of ototoxicity or nephrotoxicity or both. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> End of IV infusion; 3060 min IM. <span class="typehead">Distribution:</span> Does not cross bloodbrain barrier; accumulates in renal cortex; crosses placenta; distributed into breast milk. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 22.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform C&amp;S tests prior to initiation of therapy. Therapy may begin before test results are available; baseline
            and periodic kidney function tests; peak and trough drug levels. 
         </li>
<li>Monitor high-risk patients closely (i.e., kidney function impairment: older adults, dehydrated patients, burn patients, and
            patients receiving high doses or prolonged therapy).
         </li>
<li>Determine peak serum drug levels by drawing blood 1 h after IM injection or IV infusion begins. To determine trough serum
            drug levels, draw blood just before next scheduled dose. Desirable peak values: 610 mcg/mL; desirable trough values:
            0.52 mcg/mL. Peak values &gt;16 mcg/mL and trough values &gt;4 mcg/mL are associated with a high potential for toxicity.
         </li>
<li> 							Note: Close monitoring of serum drug concentrations is especially important for patients with fever, edema, severe burns, and anemia.
            Peak serum drug levels tend to be significantly reduced in these patients. 						
         </li>
<li>Monitor I&amp;O ratio and pattern and report significant changes. Keep patient well hydrated throughout therapy to minimize possibility
            of chemical irritation of renal tubules and to reduce risk of toxicity.
         </li>
<li>Evaluate patients before and during therapy for hearing acuity and vestibular status. Notify physician promptly if patient
            complains of any hearing loss, tinnitus, vertigo, or ataxia.
         </li>
<li>Repeat bacterial susceptibility tests if therapeutic effectiveness is not evident within 35 d.</li>
<li>Watch for S&amp;S of superinfection (see Appendix F), especially of upper respiratory tract. Also suspect overgrowth of opportunistic
            organisms if patient develops sore rectum, diarrhea, vaginal discharge, sore mouth, fever.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician immediately any roaring sounds or ringing in the ears.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>